Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Acumen Pharmaceuticals, Inc.’s names, not what it holds today.
Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
10
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name2 counted
Acumen Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
9 publishedAcumen Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Apr 26, 2016 | 9,320,793 | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 | Pharmaceuticals | Acumen Pharmaceuticals, Inc. |
| Apr 12, 2016 | 9,310,383 | Antibodies, kit and method for detecting amyloid beta oligomers | Analysis of biological materials | Acumen Pharmaceuticals, Inc. |
| Dec 22, 2015 | 9,217,024 | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production | Pharmaceuticals | Acumen Pharmaceuticals, Inc. |
| Nov 3, 2015 | 9,176,151 | Antibodies, kit and method for detecting amyloid beta oligomers | Analysis of biological materials | Acumen Pharmaceuticals, Inc. |
| Apr 14, 2015 | 9,006,283 | Methods of modifying amyloid β oligomers using non-peptidic compounds | Pharmaceuticals | Acumen Pharmaceuticals, Inc. |
| Feb 24, 2015 | 8,962,677 | Methods of restoring cognitive ability using non-peptidic compounds | Pharmaceuticals | Acumen Pharmaceuticals, Inc. |
| Aug 13, 2013 | 8,507,206 | Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta) | Analysis of biological materials | Acumen Pharmaceuticals, Inc. |
| Jun 21, 2011 | 7,964,359 | Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance | Analysis of biological materials | Acumen Pharmaceuticals, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 12, 2015 | 2015/0320860 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 | Pharmaceuticals | Acumen Pharmaceuticals, Inc. |
| Sep 17, 2015 | 2015/0260731 | ANTIBODIES, KIT AND METHOD FOR DETECTING AMYLOID BETA OLIGOMERS | Analysis of biological materials | Acumen Pharmaceuticals, Inc. · patent 9,310,383 granted from it |
| Dec 12, 2013 | 2013/0330837 | MONOCLONAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID BETA (ABETA) | Analysis of biological materials | Acumen Pharmaceuticals, Inc. |
| May 23, 2013 | 2013/0130288 | Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers | Analysis of biological materials | Acumen Pharmaceuticals, Inc. · patent 9,176,151 granted from it |
| Apr 11, 2013 | 2013/0089537 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 | Pharmaceuticals | Acumen Pharmaceuticals, Inc. · patent 9,320,793 granted from it |
| Mar 28, 2013 | 2013/0078269 | AMYLOID BETA PEPTIDES, ASSEMBLIES THEREOF, AND RELATED METHODS | Biotechnology | Acumen Pharmaceuticals, Inc. |
| Apr 28, 2011 | 2011/0098309 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | Pharmaceuticals | Acumen Pharmaceuticals, Inc. |
| Dec 2, 2010 | 2010/0303897 | NOVEL ADDL RECEPTOR POLYPEPTIDES, POLYNUCLEOTIDES AND HOST CELLS FOR RECOMBINANT PRODUCTION | Pharmaceuticals | Acumen Pharmaceuticals, Inc. · patent 9,217,024 granted from it |
| Jan 15, 2009 | 2009/0018218 | METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS | Pharmaceuticals | Acumen Pharmaceuticals, Inc. · patent 9,006,283 granted from it |
| Jan 15, 2009 | 2009/0018084 | METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS | Pharmaceuticals | Acumen Pharmaceuticals, Inc. · patent 8,962,677 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.